GLSI Form 4: Snehal Patel now holds 2,347,462 derivatives

Rhea-AI Filing Summary

Greenwich LifeSciences, Inc. (GLSI) reported a Form 4 showing that CEO, CFO, director and 10% owner Snehal Patel received a grant of 100,000 stock options on 11/13/2025. These options have an exercise price of $8.2 per share and are exercisable into 100,000 shares of common stock, with an expiration date of 11/13/2035. Following this grant, Patel beneficially owns 2,347,462 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Patel Snehal

Role CEO and CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	100,000	$0.00	--

Holdings After Transaction: Stock Options — 2,347,462 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Snehal

(Last) (First) (Middle)

C/O GREENWICH LIFESCIENCES, INC.

3992 BLUEBONNET DR., BUILDING 14

(Street)

STAFFORD TX 77477

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Greenwich LifeSciences, Inc. [ GLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$8.2	11/13/2025		A		100,000		11/13/2025	11/13/2035	Common Stock	100,000	$0	2,347,462	D

Explanation of Responses:

	/s/ Snehal Patel	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Greenwich LifeSciences (GLSI) report in this Form 4?

The filing reports that CEO, CFO, director and 10% owner Snehal Patel received a grant of 100,000 stock options on 11/13/2025 for Greenwich LifeSciences, Inc. common stock.

What is the exercise price of the new GLSI stock options granted to Snehal Patel?

The stock options granted to Snehal Patel have an exercise price of $8.2 per share for Greenwich LifeSciences, Inc. common stock.

When do Snehal Patel’s new GLSI stock options expire?

The 100,000 stock options granted on 11/13/2025 to Snehal Patel are scheduled to expire on 11/13/2035.

How many GLSI derivative securities does Snehal Patel beneficially own after this transaction?

After the reported transaction, Snehal Patel beneficially owns 2,347,462 derivative securities of Greenwich LifeSciences, Inc., held directly.

What roles does Snehal Patel hold at Greenwich LifeSciences (GLSI)?

Snehal Patel is reported as a director, CEO, CFO, and a 10% owner of Greenwich LifeSciences, Inc.

What type of security underlies the GLSI options granted to Snehal Patel?

The granted derivative securities are stock options exercisable into common stock of Greenwich LifeSciences, Inc., with 100,000 shares underlying the options.